Moderna, Inc. (MRNA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 108.85 |
| Open | 111.00 |
| Bid | 106.13 x 500 |
| Ask | 106.22 x 500 |
| Day's range | 103.52 - 108.17 |
| 52-week range | 62.55 - 142.79 |
| Volume | |
| Avg. volume | 3,777,022 |
| Market cap | 41.676B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.03 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 123.65 |
ZacksAnalysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
Investor's Business DailyAnalysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
© 2024 Yahoo. All rights reserved.